# Oragenics Inc: financial statements, quarterly

OGEN · NYSE · CIK 1174940 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ogen.md) · [Financials](/companies/ogen/financials.md) · [Filings](/companies/ogen/filings.md) · [Insiders](/companies/ogen/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ogen/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001493152-24-045067.md) | [0.0 d](/filings/0001493152-25-010389.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.8](/filings/0001493152-24-045067.md) | [11.0 d](/filings/0001493152-25-010389.md) | [0.7](/filings/0001641172-25-009464.md) | [0.9](/filings/0001641172-25-022766.md) | [0.9](/filings/0001493152-25-021257.md) | [1.7 d](/filings/0001493152-26-010282.md) | [0.3](/filings/0001493152-26-021967.md) | [0.4](/filings/0001493152-26-037749.md) | [0.9](/filings/0001493152-25-021257.md) | [0.7 d](/filings/0001493152-26-010282.md) | [0.6](/filings/0001493152-26-021967.md) | [1.2](/filings/0001493152-26-037749.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.1)](/filings/0001493152-24-045067.md) | [(12.8) d](/filings/0001493152-25-010389.md) | [(2.5)](/filings/0001641172-25-009464.md) | [(2.3)](/filings/0001641172-25-022766.md) | [(2.4)](/filings/0001493152-25-021257.md) | [(3.4) d](/filings/0001493152-26-010282.md) | [(2.0)](/filings/0001493152-26-021967.md) | [(1.7)](/filings/0001493152-26-037749.md) | [(3.1)](/filings/0001493152-25-021257.md) | [(2.5) d](/filings/0001493152-26-010282.md) | [(2.3)](/filings/0001493152-26-021967.md) | [(2.6)](/filings/0001493152-26-037749.md) |
| Interest expense | $m | [0.0](/filings/0001493152-23-040060.md) | [0.0 d](/filings/0001493152-24-011979.md) | [0.0](/filings/0001493152-24-019655.md) | [0.0](/filings/0001641172-25-022766.md) | [0.0](/filings/0001493152-25-021257.md) | [0.0 d](/filings/0001493152-26-010282.md) | [0.2](/filings/0001493152-26-021967.md) | [0.6](/filings/0001493152-26-037749.md) | [0.0](/filings/0001493152-25-021257.md) | [0.0 d](/filings/0001493152-26-010282.md) | [0.0](/filings/0001493152-26-021967.md) | [0.0](/filings/0001493152-26-037749.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(0.0)](/filings/0001493152-26-021967.md) | [(0.0)](/filings/0001493152-26-037749.md) |
| Net income | $m | [(2.0)](/filings/0001493152-24-045067.md) | [(12.7) d](/filings/0001493152-25-010389.md) | [(2.5)](/filings/0001493152-25-021257.md) | [(2.3)](/filings/0001493152-25-021257.md) | [(2.5)](/filings/0001493152-25-021257.md) | [(3.3) d](/filings/0001493152-26-010282.md) | [(2.2)](/filings/0001493152-26-037749.md) | [(2.3)](/filings/0001493152-26-037749.md) | [(3.1)](/filings/0001493152-25-021257.md) | [(2.3) d](/filings/0001493152-26-010282.md) | [(2.2)](/filings/0001493152-26-037749.md) | [(2.5)](/filings/0001493152-26-037749.md) |
| Diluted EPS | $ per share | [(0.85)](/filings/0001493152-24-045067.md) | not reported | [(0.70)](/filings/0001641172-25-009464.md) | [(15.27)](/filings/0001641172-25-022766.md) | [(11.32)](/filings/0001493152-25-021257.md) | not reported | [(3.65)](/filings/0001493152-26-021967.md) | [(3.10)](/filings/0001493152-26-037749.md) | [(1.96)](/filings/0001493152-25-021257.md) | not reported | [(0.51)](/filings/0001493152-26-021967.md) | [(0.57)](/filings/0001493152-26-037749.md) |
| Basic EPS | $ per share | [(0.85)](/filings/0001493152-24-045067.md) | not reported | [(0.70)](/filings/0001641172-25-009464.md) | [(15.27)](/filings/0001641172-25-022766.md) | [(11.32)](/filings/0001493152-25-021257.md) | not reported | [(3.65)](/filings/0001493152-26-021967.md) | [(3.10)](/filings/0001493152-26-037749.md) | [(1.96)](/filings/0001493152-25-021257.md) | not reported | [(0.51)](/filings/0001493152-26-021967.md) | [(0.57)](/filings/0001493152-26-037749.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.8](/filings/0001493152-23-040060.md) | [3.5](/filings/0001493152-25-010389.md) | [2.1](/filings/0001493152-24-019655.md) | [1.3](/filings/0001493152-24-031000.md) | [3.1](/filings/0001493152-24-045067.md) | [0.9](/filings/0001493152-26-010282.md) | [3.4](/filings/0001641172-25-009464.md) | [2.0](/filings/0001641172-25-022766.md) | [11.4](/filings/0001493152-25-021257.md) | [4.4](/filings/0001493152-26-037749.md) | [6.1](/filings/0001493152-26-021967.md) | [3.9](/filings/0001493152-26-037749.md) |
| Current assets | $m | [7.8](/filings/0001493152-23-040060.md) | [3.9](/filings/0001493152-25-010389.md) | [2.4](/filings/0001493152-24-019655.md) | [1.6](/filings/0001493152-24-031000.md) | [4.1](/filings/0001493152-24-045067.md) | [1.5](/filings/0001493152-26-010282.md) | [3.9](/filings/0001641172-25-009464.md) | [2.1](/filings/0001641172-25-022766.md) | [12.7](/filings/0001493152-25-021257.md) | [10.1](/filings/0001493152-26-037749.md) | [7.5](/filings/0001493152-26-021967.md) | [5.5](/filings/0001493152-26-037749.md) |
| Total assets | $m | [7.9](/filings/0001493152-23-040060.md) | [5.0](/filings/0001493152-25-010389.md) | [3.5](/filings/0001493152-24-019655.md) | [2.7](/filings/0001493152-24-031000.md) | [5.2](/filings/0001493152-24-045067.md) | [1.5](/filings/0001493152-26-010282.md) | [3.9](/filings/0001641172-25-009464.md) | [2.1](/filings/0001641172-25-022766.md) | [12.7](/filings/0001493152-25-021257.md) | [10.1](/filings/0001493152-26-037749.md) | [7.5](/filings/0001493152-26-021967.md) | [5.5](/filings/0001493152-26-037749.md) |
| Current liabilities | $m | [1.4](/filings/0001493152-23-040060.md) | [1.8](/filings/0001493152-24-011979.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $m | not reported | [1.8](/filings/0001493152-25-010389.md) | [0.9](/filings/0001493152-24-019655.md) | [1.4](/filings/0001493152-24-031000.md) | [2.1](/filings/0001493152-24-045067.md) | [1.7](/filings/0001493152-26-010282.md) | [3.7](/filings/0001641172-25-009464.md) | [4.3](/filings/0001641172-25-022766.md) | [2.9](/filings/0001493152-25-021257.md) | [1.8](/filings/0001493152-26-037749.md) | [1.3](/filings/0001493152-26-021967.md) | [1.8](/filings/0001493152-26-037749.md) |
| Shareholders' equity | $m | [6.5](/filings/0001493152-24-045067.md) | [3.2](/filings/0001493152-26-010282.md) | [2.6](/filings/0001493152-25-021257.md) | [1.3](/filings/0001493152-25-021257.md) | [3.1](/filings/0001493152-25-021257.md) | [(0.2)](/filings/0001493152-26-037749.md) | [0.1](/filings/0001493152-26-037749.md) | [(2.1)](/filings/0001493152-26-037749.md) | [9.8](/filings/0001493152-25-021257.md) | [8.3](/filings/0001493152-26-037749.md) | [6.2](/filings/0001493152-26-037749.md) | [3.7](/filings/0001493152-26-037749.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,503) d](/filings/0001493152-24-045067.md) | [(1,103) d](/filings/0001493152-25-010389.md) | [(3,064)](/filings/0001641172-25-009464.md) | [(1,545) d](/filings/0001641172-25-022766.md) | [(1,970) d](/filings/0001493152-25-021257.md) | [(2,018) d](/filings/0001493152-26-010282.md) | [(2,112)](/filings/0001493152-26-021967.md) | [(1,314) d](/filings/0001493152-26-037749.md) | [(2,985) d](/filings/0001493152-25-021257.md) | [(2,835) d](/filings/0001493152-26-010282.md) | [(2,201)](/filings/0001493152-26-021967.md) | [(2,187) d](/filings/0001493152-26-037749.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [1,946](/filings/0001493152-23-040060.md) | [2,205](/filings/0001493152-24-019655.md) | [2,025](/filings/0001493152-24-031000.md) | [2,356](/filings/0001493152-24-045067.md) | [3,496](/filings/0001641172-25-009464.md) | [151](/filings/0001641172-25-022766.md) | [218](/filings/0001493152-25-021257.md) | [607](/filings/0001493152-26-021967.md) | [732](/filings/0001493152-26-037749.md) | [1,561](/filings/0001493152-25-021257.md) | [4,301](/filings/0001493152-26-021967.md) | [4,429](/filings/0001493152-26-037749.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,511,957 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037749.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.